Last reviewed · How we verify
NCT01808820
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
Completed
Phase 1
Last updated 20 July 2022
What this trial tests
Phase 1 trial testing Dendritic Cell Vaccine in Malignant Glioma in 20 participants. Completed in 16 July 2022.
Timeline
21 August 2013
Primary endpoint
7 November 2018
7 November 2018
16 July 2022
Quick facts
| Lead sponsor | Macarena De La Fuente, MD |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 21 August 2013 |
| Primary completion | 7 November 2018 |
| Estimated completion | 16 July 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dendritic Cell Vaccine — full drug profile →
- Tumor Lysate — full drug profile →
- Imiquimod (IMIQUIMOD) — full drug profile →
- Leukapheresis — full drug profile →
Conditions studied
- Malignant Glioma — all drugs for Malignant Glioma →
- Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
- Anaplastic Astrocytoma — all drugs for Anaplastic Astrocytoma →
- High Grade Glioma — all drugs for High Grade Glioma →
Sponsor
Macarena De La Fuente, MD — full company profile →
Who can join
Adults 13 to 99, any sex, with Malignant Glioma or Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research study is to evaluate an investigational vaccine using patent-derived dendritic cells (DC) to treat malignant glioma or glioblastoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Li K, Shi H, Zhang B, Ou X, et al · · 2021 · cited 687× · PMID 34620838 · DOI 10.1038/s41392-021-00670-9 -
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7 -
Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.
Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, et al · · 2019 · cited 145× · PMID 31031762 · DOI 10.3389/fimmu.2019.00766 -
Advances in Glioblastoma Therapy: An Update on Current Approaches.
Angom RS, Nakka NMR, Bhattacharya S. · · 2023 · cited 140× · PMID 38002496 · DOI 10.3390/brainsci13111536 -
Research progress on dendritic cell vaccines in cancer immunotherapy.
Yu J, Sun H, Cao W, Song Y, et al · · 2022 · cited 130× · PMID 35074008 · DOI 10.1186/s40164-022-00257-2 -
Trial Watch: Toll-like receptor agonists for cancer therapy.
Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, et al · · 2013 · cited 127× · PMID 24083080 · DOI 10.4161/onci.25238 -
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.
Iribarren K, Bloy N, Buqué A, Cremer I, et al · · 2016 · cited 98× · PMID 27141345 · DOI 10.1080/2162402x.2015.1088631 -
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.
Xun Y, Yang H, Kaminska B, You H. · · 2021 · cited 96× · PMID 34715891 · DOI 10.1186/s13045-021-01191-2
Verify or expand the search:
- PubMed search for NCT01808820
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dendritic Cell Vaccine
Trials testing the same drug.
- NCT06805656 — Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals · Phase 2 · not yet recruiting
- NCT05321940 — Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias · Phase 1 · withdrawn
- NCT05767684 — Neoantigen Derived DCs as Cancer Treatment · Phase 1 · unknown
- NCT01902771 — Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors · Phase 1 · terminated
Other recruiting trials for Malignant Glioma
Currently open trials in the same condition.
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07447531 — T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas · NA · recruiting
- NCT06470711 — Mapping of Electrical Properties in the Brain · recruiting
- NCT05717153 — Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma · EARLY_PHASE1 · recruiting
- NCT05030298 — Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial · Phase 1 · recruiting
Other Macarena De La Fuente, MD trials
Trials by the same sponsor.
- NCT01803152 — Dendritic Cell Vaccine for Children and Adults With Sarcoma · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT01808820 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Macarena De La Fuente, MD
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01808820.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing